نتایج جستجو برای: bone marker

تعداد نتایج: 428975  

Journal: :Osteoarthritis and Cartilage 2018

Journal: :Alimentary pharmacology & therapeutics 2004
N Franchimont V Putzeys J Collette S Vermeire P Rutgeerts M De Vos A Van Gossum D Franchimont R Fiasse P Pelckmans M Malaise J Belaiche E Louis

BACKGROUND Crohn's disease is associated with low bone mineral density and altered bone metabolism. AIM To assess the evolution of bone metabolism in Crohn's disease patients treated with infliximab. METHODS We studied 71 Crohn's disease patients treated for the first time with infliximab for refractory Crohn's disease. Biochemical markers of bone formation (type-I procollagen N-terminal pr...

Journal: :Nigerian journal of physiological sciences : official publication of the Physiological Society of Nigeria 2006
E C Azinge D M Bolarin

Osteocalcin or bone gamma-carboxyglutamic acid (gla) protein and Bone-specific alkaline phosphatase (b-AP) total protein levels were evaluated as indicators of bone turnover in twenty patients with sickle cell haemoglobinopathies and in twenty normal healthy individuals. The serum bone-specific alkaline phosphatase total protein level was measured by immunoradiometric (IRMA) method. The concent...

Journal: :Arquivos brasileiros de endocrinologia e metabologia 2010
Patrícia Dreyer José Gilberto H Vieira

To asses fracture risk, bone mineral density (BMD) measured by dual-energy X-ray absorptiometry (DXA) is the most commonly used tool. The search for clinical risk factors is also advised and can provide a 10-year fracture probability (FRAX model). Another important determinant of bone strength is bone remodeling. High bone remodeling rates have been associated with a higher fracture risk and bo...

Journal: :Journal of the National Cancer Institute 2005
Janet E Brown Richard J Cook Pierre Major Allan Lipton Fred Saad Matthew Smith Ker-Ai Lee Ming Zheng Yong-Jiang Hei Robert E Coleman

BACKGROUND Whether bone markers have prognostic value in patients with bone metastases is unknown. We investigated this question in patients with bone metastases secondary to prostate cancer and to non-small-cell lung cancer (NSCLC) and other solid tumors assigned to the placebo arms of two phase III trials of zoledronic acid. METHODS Levels of the urinary bone resorption marker N-telopeptide...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید